Sequenom Laboratories Launches The HerediT® UNIVERSAL Test In Collaboration With Recombine

Carrier Screening Testing Service Offers Comprehensive Genetic Information

San Diego, CA /PRNewswire/ - Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, and Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, today announced the launch of the HerediT® UNIVERSAL carrier screening test as a service to ordering physicians. The launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.

"Carrier screening remains an important part of genetic risk assessment and is now being utilized by physicians for patients planning families," said William Welch, President and Chief Executive Officer of Sequenom, Inc.

The HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations. Current options are limited to single gene testing or tests that can identify approximately 100 hereditary conditions. This new offering can be performed preconception or at any time during pregnancy.

"Though individually rare, genetic disorders are collectively common and are a significant cause of childhood mortality," said James Grifo, M.D., Ph.D., Program Director of New York University, Fertility Center. "An expanded carrier screening test provides an opportunity to look beyond a patient's family history or ethnic predispositions to particular diseases, which is increasingly valuable as the obstetrics and gynecology (OB/GYN) physician community incorporates broader screening into its routine standard of care."

"We are excited to collaborate with Sequenom Laboratories, the market leader in noninvasive prenatal testing, to bring this expanded carrier screening technology to the OB/GYN and maternal fetal medicine space," said Alex Bisignano, Chief Executive Officer of Recombine. "This strategic alliance will help us reach more patients, and enable them to use comprehensive genetic testing and counseling services to make informed decisions in family planning."

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information.

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, MaterniT21® PLUS, SensiGene® and VisibiliT™, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. To learn how Sequenom is interpreting the genome for improving the lives of patients everywhere, visit www.sequenom.com and follow @SequenomLabs.

About Recombine, Inc.

Recombine is a clinical genetic testing company dedicated to helping patients and providers make informed decisions based on comprehensive and clinically actionable genetic testing results and in-depth genetic counseling. Recombine joins experts in genetics, fertility, and computer science brought together with one goal in mind: to improve health outcomes with personalized genomic testing. CarrierMap is Recombine's expanded carrier screening platform for over 250 genetic diseases designed for patients and gamete donors of all ethnicities. To learn how Recombine is leveraging the unprecedented power of advanced technologies, visit www.recombine.com and follow @Recombine.

SEQUENOM®, Sequenom Laboratories™, HerediT®, MaterniT21® PLUS, SensiGene® and VisibiliT™, are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the development of innovative products and services, the obstetrics and gynecology (OB/GYN) physician community incorporating broader screening into its routine standard of care and the ability to reach more patients and enable them to use comprehensive genetic testing and counseling services to make informed decisions in planning their families. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.